How long did Lutetium Lu-177 Vipivotide Tetraxetan take from discovery to FDA approval?

Approximately 17–18 years from early preclinical research (~2005) to FDA accelerated approval (May 2023). Clinical development alone—from first-in-human studies to regulatory approval—spanned 7–8 years (2015–2023), driven by the urgent unmet need in advanced prostate cancer.

Why did the FDA grant accelerated approval instead of standard approval?

Accelerated approval was justified by the significant unmet medical need in metastatic castration-resistant prostate cancer and the robust Phase 3 VISION trial data showing a hazard ratio of 0.40 for radiographic progression-free survival. The accelerated pathway brought the therapy to patients faster, conditional on post-approval confirmatory studies.

Is Lutetium Lu-177 Vipivotide Tetraxetan approved worldwide?

Approved by the FDA (US, May 2023) and EMA (EU, June 2023). Health Canada has not yet approved it as of 2024. Other jurisdictions (Australia, Japan, etc.) have ongoing regulatory interactions. Approval status varies; check local health authority guidance before treatment.

What is the ongoing regulatory requirement after FDA approval?

[The FDA conditional approval mandates completion of confirmatory post-approval trials](https://www.fda.gov/drugs/resources-information-drugs-and-drugs-conditions/fda-approves-pluvicto-prostate-cancer), with final data expected by 2026. This ensures long-term efficacy and safety in broader populations are documented.

How many clinical trials have been conducted on this compound?

Over 13 registered clinical trials have evaluated Lutetium Lu-177 Vipivotide Tetraxetan, spanning phase 1–3 efficacy studies and post-approval expansion trials in earlier-stage prostate cancer and combination regimens. The pivotal VISION trial enrolled 831 patients across multiple countries.

Lutetium Lu-177 Vipivotide Tetraxetan: Regulatory Timeline & Approval History

Lutetium Lu-177 Vipivotide Tetraxetan (Pluvicto®) is a radioligand therapy approved by the FDA and EMA for men with PSMA-positive metastatic castration-resistant prostate cancer. This peptide-based therapeutic represents a watershed moment in radiopharmaceutical development, combining a beta-emitting radionuclide with a targeting peptide to deliver precision oncology treatment. The regulatory pathway from preclinical research through global authorization took over a decade, involving 13+ clinical trials and intensive collaboration between academic centres, industry, and regulators. Understanding this timeline reveals how modern peptide therapeutics navigate the complex approval landscape.

Discovery & Early Development (2005–2015)

The foundational science behind Lutetium Lu-177 Vipivotide Tetraxetan began in earnest in the mid-2000s, when researchers recognized that PSMA (prostate-specific membrane antigen) could serve as a precision target for radioligand therapy in advanced prostate cancer. PSMA, highly expressed on prostate cancer cells, became the focus of targeted radiotherapy development across multiple institutions.

The peptide component—vipivotide—is a small molecule PSMA-binding peptide derived from urea-based pharmacophores. The chelator (tetraxetan) was engineered to stably bind lutetium-177, a medium-energy beta emitter ideal for therapeutic applications. Early preclinical studies in the 2010s demonstrated proof-of-concept in xenograft models, showing tumour uptake and therapeutic benefit. These foundational papers established the biological rationale for clinical translation.

First-in-Human & Phase 1 Studies (2015–2017)

The first human dosimetry and safety studies began around 2015–2016 at leading European cancer centres. These phase 1 trials enrolled small cohorts of men with metastatic castration-resistant prostate cancer (mCRPC) refractory to conventional therapies, including androgen receptor inhibitors and chemotherapy. Early data showed promising signal: selective uptake in PSMA-positive lesions with acceptable safety profiles.

A pivotal early study from this era, published in the European Journal of Nuclear Medicine and Molecular Imaging, reported imaging and safety data supporting dose escalation. These trials refined dosing regimens and identified patient selection criteria (PSMA-positive disease confirmed on baseline imaging).

Phase 2 Expansion Trials (2017–2019)

By 2017, multiple phase 2 studies were underway across Europe and the United States. These trials enrolled larger cohorts (typically 30–100 patients per arm) to evaluate efficacy endpoints including PSA response, radiographic progression-free survival, and safety. The goal was to identify the optimal dose and treatment schedule for pivotal phase 3 testing.

Key findings from this era included:

Objective response rates (PSA ≥50% decline) in 40–60% of patients
Median progression-free survival improvements compared to historical controls
Grade 3–4 toxicity rates manageable with standard supportive care

These results were presented at major oncology conferences (ASCO, ESMO) and generated significant interest from regulators and clinicians, validating the therapeutic hypothesis.

Phase 3 VISION Trial & Regulatory Submissions (2019–2022)

The pivotal phase 3 VISION trial, a randomized controlled study, enrolled 831 men with mCRPC and PSMA-positive disease across multiple countries. This landmark trial compared Lutetium Lu-177 Vipivotide Tetraxetan plus standard-of-care androgen receptor pathway inhibition (abiraterone or enzalutamide) versus standard care alone.

VISION enrolled participants between 2017–2019. The primary efficacy endpoint was radiographic progression-free survival (rPFS). Secondary endpoints included overall survival, PSA response, and quality-of-life measures. The trial met its primary endpoint, demonstrating a median rPFS of 8.7 months with Lutetium Lu-177 Vipivotide Tetraxetan versus 3.3 months with standard care alone—a hazard ratio of 0.40 (95% CI: 0.29–0.57).

Results were published in the New England Journal of Medicine in December 2021, providing robust evidence for regulatory submission. Regulatory dossiers were prepared and submitted to the FDA and EMA in late 2021 and early 2022.

FDA Approval & EMA Authorization (2022–2023)

On May 27, 2023, the FDA granted accelerated approval to Lutetium Lu-177 Vipivotide Tetraxetan (branded Pluvicto®) for men with PSMA-positive mCRPC. The approval was notable for:

Accelerated pathway classification, reflecting the unmet medical need
Conditional on post-approval confirmatory trials
Risk Evaluation and Mitigation Strategy (REMS) requirements due to radiation exposure

The European Medicines Agency (EMA) followed with authorization in June 2023 under the centralized procedure. EMA approval included classification as an orphan medicinal product, reflecting the specialized indication in advanced prostate cancer.

Health Canada has not yet approved Lutetium Lu-177 Vipivotide Tetraxetan as of 2024, though regulatory interactions are ongoing.

Post-Approval Clinical Development (2023–Present)

Since FDA/EMA approval, the regulatory landscape continues to evolve:

Confirmatory Trials: The FDA conditional approval mandates completion of VISION follow-up studies evaluating long-term efficacy and safety, with final data expected in 2025–2026.

Real-World Evidence: Post-marketing surveillance and registry studies across Europe and the US are collecting data on treatment patterns, durability, and late toxicities (particularly haematologic and renal outcomes) in broader populations.

Trial Expansion Studies: Over 13 clinical trials are registered globally investigating Lutetium Lu-177 Vipivotide Tetraxetan in earlier disease stages (hormone-sensitive prostate cancer, biochemical recurrence) and combination regimens. These studies aim to define optimal patient populations and expand the treatment landscape.

Manufacturing & Supply: Scaled production and distribution agreements have been finalized to meet global demand, with manufacturing partnerships across North America and Europe.

Regulatory Classification & Current Status

United States: FDA-approved (accelerated approval, May 2023) with mandatory post-approval confirmatory trial data required by 2026.

European Union: EMA-authorised (June 2023) with orphan medicinal product designation.

Canada: Not approved; regulatory pathway under review.

Lutetium Lu-177 Vipivotide Tetraxetan is classified as an investigational new drug in jurisdictions where approval has not been granted, and as an approved therapeutic in the US and EU markets.

Key Milestones Summary Table

| Year | Milestone | Details | |------|-----------|----------| | 2005–2015 | Preclinical development | PSMA-targeting peptide engineering, radionuclide selection | | 2015–2017 | Phase 1 trials | First-in-human dosimetry and safety studies | | 2017–2019 | Phase 2 expansion | Multi-centre efficacy and dose-finding studies | | 2019–2021 | VISION Phase 3 trial | Pivotal randomized controlled trial (831 patients) | | Dec 2021 | VISION publication | Results published in NEJM; rPFS hazard ratio 0.40 | | May 2023 | FDA approval | Accelerated approval for PSMA-positive mCRPC | | June 2023 | EMA authorization | Orphan medicinal product status granted | | 2023–2025 | Post-approval studies | Confirmatory trials, real-world evidence, expansion studies |

Why the Timeline Matters for Patients & Clinicians

Understanding this regulatory timeline is valuable for several reasons:

Clinical Urgency: Men with mCRPC face rapid disease progression and limited options. The accelerated approval pathway, while conditional, brought Lutetium Lu-177 Vipivotide Tetraxetan to patients years earlier than a standard approval track would have.

Evidence Quality: The VISION trial represents one of the largest and most rigorous radioligand therapy studies to date, with long-term follow-up data continuing to accumulate. Early-adopter centres now have 2+ years of real-world experience, informing optimal use.

Manufacturing & Access: FDA and EMA approval unlocked significant manufacturing investment. Global supply chains are now established, reducing wait times and ensuring consistent product quality across markets.

Future Indications: The regulatory precedent set by Lutetium Lu-177 Vipivotide Tetraxetan approval has accelerated development of next-generation PSMA-targeted radiotherapies and earlier-stage disease studies.

Related Compounds in Development

Lutetium Lu-177 Vipivotide Tetraxetan is part of a broader class of radioligand therapies. Related PSMA-targeting compounds and alternative radionuclide platforms (e.g., actinium-225 PSMA agents) are in clinical development, offering complementary or alternative mechanisms.

The regulatory approval of Lutetium Lu-177 Vipivotide Tetraxetan has validated the PSMA-targeting paradigm, accelerating clinical translation of related molecules and establishing a competitive radiopharmaceutical landscape.

Glossary Terms

PSMA (Prostate-Specific Membrane Antigen): A cell-surface protein overexpressed in prostate cancer. It serves as a targeting antigen for both imaging (PET/SPECT) and therapeutic radiopharmaceuticals. Learn more.

Radioligand Therapy: A targeted cancer treatment combining a targeting molecule (ligand) with a therapeutic radionuclide to deliver radiation directly to tumour cells. Learn more.

Accelerated Approval: A regulatory pathway allowing faster approval of drugs addressing unmet medical needs, conditional on post-approval confirmatory studies. Learn more.

Lutetium Lu-177 Vipivotide Tetraxetan Regulatory & Approval Timeline